With over 30 years of experience investing in novel life science technologies, we understand how challenging it can be to turn a great idea into a great company.
We are comfortable evaluating and taking significant scientific risks. Our team and network of advisors includes a number of former executives with first-hand experience of these challenges, who are available to provide support and advice when it is needed.
We also understand that building a successful company takes time and patience. Our team is committed to building real value over the long-term.
"Abingworth is an excellent investor for GammaDelta Therapeutics. Using strong scientific expertise and astute business sense they drove the seed investment with King’s College and the Crick institute and then our highly productive collaboration with Takeda. High quality science and ethical behaviour form the foundation of day-by-day activities at Abingworth and it is extremely reassuring to have such partners."
Paolo Paoletti, CEO of GammaDelta Therapeutics
"I feel fortunate to have Abingworth as an investor in Wilson Therapeutics. Their in-depth knowledge of drug development in combination with being very well connected in the life science industry adds great value to our company."
Jonas Hansson, CEO of Wilson Therapeutics
"As one of Tizona’s early investors, Abingworth has been a very engaged partner, providing support and prodigious resources to the company. They also bring a deep knowledge of the industry and an extensive network that has benefited us greatly."
Pablo Cagnoni, CEO of Tizona Therapeutics
"Abingworth not only devised and executed a thorough diligence process, but as our lead Series A investor, galvanized a strong long-term investor syndicate. Through their expansive network, they also helped us secure the site of our new corporate headquarters in an intensely competitive real estate market."
Grant Pickering, President and CEO of SutroVax
"Working with Abingworth to build CRISPR Therapeutics is a pleasure. They are incredibly supportive in shaping the company, which aims to lead the highly dynamic and competitive environment of gene editing."
Rodger Novak, Chairman of CRISPR Therapeutics